Skip to content

HIV Self-testing in Implementation PrEP Study

ImPrEP Sub-study - HIV Self-Testing to Increase Combination Prevention Demand in the ImPrEP Project: an Adaptative Randomized Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03642314
Enrollment
876
Registered
2018-08-22
Start date
2018-09-30
Completion date
2022-09-30
Last updated
2018-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Prevention

Keywords

pre exposure prophylaxis, men who have sex with men

Brief summary

This is a sub-study of an ongoing PrEP study ( HIV PrEP for men who have sex with men - MSM - and transgender women - TGW: a demonstrative project in Brazil, Peru and Mexico - ImPrEP). MSM/TGW enrolled to ImPrEP Study at the selected sites, who agree to participate in this HIV Self Test (HIVST) sub-study, will be 1:1 randomized at the third study visit either to receive 5 HIVST+voucher (intervention arm) or 5 vouchers alone (control arm) to secondarily distribute into their MSM/TGW network. All vouchers are numbered invitations for priority access to individualized HIV risk assessment and combination prevention services, including PrEP, at the ImPrEP sites. Study population comprises ImPrEP participants and their referred peers. Sample size is going to be determined at an interim analysis performed when each city has enrolled 70 participants. Trial participants will be at maximum 876 (438 intervention and 438 in the control arm) MSM and TGW included in the ImPrEP Study who received PrEP for at least 6 months in the sites from Rio de Janeiro and Lima. The study is designed as a multicenter, open, adaptative, randomized trial. The main study outcome is the voucher redemption proportion by arm.

Interventions

DIAGNOSTIC_TESTHIV self test kit

HIVST receptor will be invited to priority access to PrEP sites

Sponsors

Oswaldo Cruz Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* individuals who were included in the ImPrEP Study * performed at least 3 study visits, * accepted to participate in this sub study, * provide informed consent form

Exclusion criteria

* Individuals included into ImPrEP as a result of HIVST secondary distribution

Design outcomes

Primary

MeasureTime frame
voucher redemption proportion by arm2 years

Contacts

Primary ContactValdilea Veloso, PhD
valdilea.veloso@ini.fiocruz.br+552122707064

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026